KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash from Financing Activities (2018 - 2025)

Castle Biosciences' Cash from Financing Activities history spans 7 years, with the latest figure at -$4.6 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 14.78% year-over-year to -$4.6 million; the TTM value through Dec 2025 reached -$7.0 million, down 213.37%, while the annual FY2025 figure was -$7.0 million, 213.37% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$4.6 million at Castle Biosciences, down from -$919000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $10.6 million in Q1 2024 and bottomed at -$5.4 million in Q4 2024.
  • The 5-year median for Cash from Financing Activities is $176000.0 (2021), against an average of $190850.0.
  • The largest annual shift saw Cash from Financing Activities crashed 695.24% in 2022 before it skyrocketed 1762.22% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $126000.0 in 2021, then plummeted by 695.24% to -$750000.0 in 2022, then crashed by 339.6% to -$3.3 million in 2023, then tumbled by 63.33% to -$5.4 million in 2024, then grew by 14.78% to -$4.6 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Cash from Financing Activities are -$4.6 million (Q4 2025), -$919000.0 (Q3 2025), and $101000.0 (Q2 2025).